EMEND for Injection
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $189,234 | 51 | 0 |
| 2019 | $33,579 | 11 | 0 |
| 2017 | $25,088 | 11 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $247,901 | 73 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 4, Open-label, Single Arm Study to Evaluate the Safety and Tolerability of a Three-day Fosaprepitant Regimen Administered for the Prevention of Chemotherapy-Induced Nausea and Vomiting CINV in Pediatric Participants Receiving Emetogenic Chemotherapy | Merck Sharp & Dohme Corporation | $195,964 | 0 |
| Nausea and Vomiting Sec'dy to FOLFIRINOX Chemotherapy in GI Cancer Patients | Merck Sharp & Dohme Corporation | $26,849 | 0 |
| A Phase IIb, Partially-Blinded, Randomized, Active Comparator-Controlled Study to Evaluate the Pharmacokinetics,Pharmacodynamics, Safety and Tolerability of Fosaprepitant in Pediatric Patients for the Prevention of Chemotherapy-Induced Nausea and Vomiting CINV Associated with Emetogenic Chemotherapy | Merck Sharp & Dohme Corporation | $15,410 | 0 |
| A phase III, randomized, placebo-controlled clinical trial to study the efficacy and safety of MK-0517,fosaprepitant and ondansetron versus ondansetron for the prevention of chemotherapy-induced nausea and vomiting CINV in pediatric subjects receiving emetogenic chemotherapy | Merck Sharp & Dohme Corporation | $7,684 | 0 |
| Phase II, double-blind, placebo-controlled, crossover study evaluating a 5HT3 antagonist plus dexamethasone with or without fosaprepitant in patients with advanced NSCLC receiving carboplatin based chemotherapy | Merck Sharp & Dohme Corporation | $1,994 | 0 |
Top Doctors Receiving Payments for EMEND for Injection
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Hackensack, NJ | $247,901 | 73 |
Manufacturing Companies
- Merck Sharp & Dohme Corporation $247,901
Product Information
- Type Drug
- Total Payments $247,901
- Total Doctors 0
- Transactions 73
About EMEND for Injection
EMEND for Injection is a drug associated with $247,901 in payments to 0 healthcare providers, recorded across 73 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2017 to 2020. In 2020, $189,234 was paid across 51 transactions to 0 doctors.
The most common payment nature for EMEND for Injection is "Unspecified" ($247,901, 100.0% of total).
EMEND for Injection is associated with 5 research studies, including "A Phase 4, Open-label, Single Arm Study to Evaluate the Safety and Tolerability of a Three-day Fosaprepitant Regimen Administered for the Prevention of Chemotherapy-Induced Nausea and Vomiting CINV in Pediatric Participants Receiving Emetogenic Chemotherapy" ($195,964).